Magnetic resonance imaging in clinical trials

Area of Science:

• Neurology
• Radiology
• Biomarkers

Background:

• Magnetic resonance imaging (MRI) offers noninvasive detection of brain disorders.
• Its sensitivity makes it valuable for assessing treatment efficacy.
• MRI is increasingly utilized in clinical trials for neurological conditions.

Purpose of the Study:

• To review recent clinical trials in neurological diseases.
• To focus on the use of MRI in assessing treatment outcomes.
• To highlight the role of MRI as a biomarker.

Main Methods:

• Review of clinical trials utilizing MRI.
• Analysis of volumetric and functional MRI for Alzheimer's disease.
• Assessment of perfusion-weighted and diffusion-weighted imaging in stroke.
• Evaluation of lesion load in multiple sclerosis.
• Inclusion of advanced quantitative MRI techniques.

Main Results:

• Volumetric and functional MRI are robust biomarkers for anti-Alzheimer treatments, showing efficacy of cholinesterase inhibitors.
• Perfusion and diffusion imaging help quantify the ischemic penumbra in acute ischemic stroke.
• T2 or FLAIR lesion load is standard for evaluating multiple sclerosis therapies.
• Emerging techniques like MR volumetry and spectroscopy are gaining traction.

Conclusions:

• MRI serves as a crucial surrogate marker for treatment response in neurological disorder trials.
• MRI can potentially reduce the sample size and duration of clinical trials.
• Advanced MRI techniques offer precise and sensitive outcome measures.